Iovance Biotherapeutics, Inc. (IOVA) — Financial statements
Income statement, balance sheet, and cash flow for Iovance Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 264↑60.6% | 164↑13699.0% | 1 | 0.00 | 0.00 | |
| Cost of Revenue | 7↓94.1% | 124↑1052.9% | 11 | 0.00 | 0.00 | |
| Gross Profit | 256↑539.3% | 40↑518.9% | -10 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 300↑6.4% | 282↓17.9% | 344↑16.7% | 295↑13.8% | 259 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 104↑24.4% | 84 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 152↓0.5% | 153↑43.1% | 107↑2.7% | 104↑24.4% | 84 | |
| Other Expenses | 207 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 660↑51.5% | 435↓3.5% | 451↑13.1% | 399↑16.4% | 343 | |
| Total Costs & Expenses | 667↑19.2% | 559↑21.1% | 462↑15.8% | 399↑16.4% | 343 | |
| Operating Results | ||||||
| Operating Income | -403↓2.0% | -395↑14.2% | -461↓15.5% | -399↓16.4% | -343 | |
| Depreciation & Amortization | 36↓17.6% | 44↑31.6% | 33↑56.7% | 21↑51.2% | 14 | |
| EBITDA | -357↓1.5% | -352↑17.7% | -427↓13.2% | -378↓14.9% | -329 | |
| EBIT | -393↑0.6% | -395↑14.2% | -461↓15.5% | -399↓16.4% | -343 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 20↑55.4% | 13 | 0.00↓100.0% | 0.45 | |
| Interest Income | 0.00↓100.0% | 20↑55.4% | 13↑337.0% | 3↑561.9% | 0.45 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 3 | 0.00 | |
| Non-Operating Income | -10 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 10↓49.2% | 20↑55.4% | 13↑337.0% | 3↑561.9% | 0.45 | |
| Income Before Tax | -393↓4.8% | -375↑16.2% | -448↓13.0% | -396↓15.7% | -342 | |
| Income Tax Expense | -2↑26.8% | -3↑18.7% | -3 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -391↓5.1% | -372↑16.2% | -444↓12.2% | -396↓15.7% | -342 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -391↓5.1% | -372↑16.2% | -444↓12.2% | -396↓15.7% | -342 | |
| Bottom-Line Net Income | -391↓5.1% | -372↑16.2% | -444↓12.2% | -396↓15.7% | -342 | |
| EPS (Basic) | -1.09↑14.8% | -1.28↑32.3% | -1.89↑24.1% | -2.49↓11.7% | -2.23 | |
| EPS (Diluted) | -1.09↑14.8% | -1.28↑32.3% | -1.89↑24.1% | -2.49↓11.7% | -2.23 | |
| Weighted Average Shares | 357↑23.3% | 290↑23.3% | 235↑47.6% | 159↑3.8% | 153 | |
| Weighted Average Diluted Shares | 357↑23.3% | 290↑23.3% | 235↑47.6% | 159↑3.8% | 153 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.